Guidelines - Endocrine System

Please select from the following Guidelines.

Insulin Prescription and Administration Record (IPAR)

Documentation for insulin recording including guidance on management of hyper and hypo glycaemia

Insulin Prescription and Administration Record (IPAR)Download File
(IPAR Form 2016 V5.pdf)

Date Uploaded: 15/06/2017

Home / Guidelines

Denosumab shared care protocol 2016

Denosumab is the first of a new class of agents for the treatment of osteoporosis. It is a fully human monoclonal antibody, which inhibits bone resorption by specifically targeting RANK Ligand in the bone matrix, thus mimicking the body’s natural bone protection mechanism. 5 year efficacy and safety data for use in postmenopausal osteoporosis - this document provides advice on prescribing of this product for GP practices

Denosumab shared care protocol 2016Download File
(2016 Oct Denosumab Shared Care Protocol.pdf)

Date Uploaded: 05/12/2016

Home / Guidelines

Type 2 Diabetes Treatment Algorithm & Drug Summary

NHS D&G Treatment algorithm for type 2 diabetes mellitus including a short summary of the characteristics of non-insulin treatments.

Type 2 Diabetes Treatment Algorithm & Drug SummaryDownload File
(T2 DM combined treatment algorithm & drug summary.pdf)

Date Uploaded: 19/10/2016

Home / Guidelines

Miniguide to DEXA referral for postmenopausal women and men %0yrs or above

This is a quick reference guide for initial DEXA referral for postmenopausal women and men aged 50 or above

Miniguide to DEXA referral for postmenopausal women and men %0yrs or aboveDownload File
(Osteoporosis_Miniguide_for_initial_DEXA_referral_and_management_2015[2].pdf)

Date Uploaded: 02/11/2015

Home / Guidelines

Guideline for patients on long term bisphosphonates or denosumab

Guidance for Patients on oral bisphosphonates or subcutaneous Denosumab for osteroporosis > 5 years duration

Guideline for patients on long term bisphosphonates or denosumabDownload File
(Osteoporosis_-_guidelines_for_those_on_longterm_bisphosphonates_or_Denosumab_May_2015[1]_1.pdf)

Date Uploaded: 08/06/2015

Home / Guidelines

Safe prescribing of strontium during acute illness

This guidance provides advice relating to the safe prescribing of strontium for osteoporosis

Safe prescribing of strontium during acute illnessDownload File
(2014_Dec_Strontium_Ranelate_and_Acute_Illness_Miniguide_1.pdf)

Date Uploaded: 08/06/2015

Home / Guidelines

Osteoporosis Mangement Guideline and DEXA referral criteria

Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above

Osteoporosis Mangement Guideline and DEXA referral criteriaDownload File
(Osteoporosis_-_guideline_for_DEXA_referral_and_initial_management_in_D_&_G_May_2015.pdf)

Date Uploaded: 08/06/2015

Home / Guidelines

Guideline for patients on long term bisphosphonates or denosumab

Guidance for review of patients on oral bisphosphonates or subcutaneous Denosumab for osteroporosis > 5 years

Guideline for patients on long term bisphosphonates or denosumabDownload File
(Osteoporosis_-_guidelines_for_those_on_longterm_bisphosphonates_or_Denosumab_May_2015[1].pdf)

Date Uploaded:

Home / Guidelines

Home | About | Glossary | Web Links | Local Links | Site Map | Disclaimer | Contact

© Primary Care Development | Crichton Hall | Bankend Road | Dumfries | Dumfries & Galloway | Scotland | DG1 4TG

Valid CSS!Valid HTML 4.01 Transitional

Website design, hosting and maintenance by:
NJ Web Design